ClinicalTrials.gg
CompletedNCT02500706onset®8Updated Jun 12, 2019Results posted

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 152 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-12.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
Largest of 87
1,108 · median 50
Started
2016
with 4 others
Phase 3
24 of 87
none open now
Registered
58th of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 58th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 1,108 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Male or female, age greater than or equal to 18 years ( for Japan and Taiwan: age greater than or equal to 20 years) at the time of signing - Type 1 Diabetes Mellitus (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) 12 months or more prior to screening - Currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1) - Currently treated with a basal insulin analogue for at least 4 months prior to screening (Visit 1) - 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory - less than or equal to 35.0 kg/m\^2 Exclusion Criteria: - Within the past 180 days any of the following: myocardial infarction, stroke or hospitalization for unstable angina and/or - Subjects presently classified as being in (NYHA) Class IV Currently planned coronary, carotid or peripheral artery revascularisation - Diabetic ketoacidosis requiring hospitalisation within the last 180 days prior to screening (Visit 1) - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of three months before screening (Visit 1)

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,108 participants (actual)

Study arms

  • Experimental
    Mealtime faster-acting insulin aspart and insulin degludec

    Drug: Faster-acting insulin aspart · Drug: insulin degludec

  • Active comparator
    Mealtime NovoRapid® and insulin degludec

    Drug: insulin aspart · Drug: insulin degludec

  • Experimental
    Postmeal faster-acting insulin aspart and insulin degludec

    Drug: Faster-acting insulin aspart · Drug: insulin degludec

Interventions

  • Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.

  • Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.

  • Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c 26 Weeks After Randomisation

    Change from baseline (week 0) in HbA1c was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)

    The 1-hour PPG increment was analysed based on the laboratory-measured values in the meal test, and was derived using the 1-hour PPG measurement minus the pre-prandial plasma glucose (PG). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  2. Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation

    The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  3. Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation

    The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  4. Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0%) 26 Weeks After Randomisation

    The percentage of subjects who achieved the HbA1c target of \<7.0% 26 weeks after randomisation. Subjects without an HbA1c measurement at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  5. Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia) 26 Weeks After Randomisation

    The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  6. Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia and Minimal Weight Gain [<3.0%]) 26 Weeks After Randomisation

    The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia and with minimal weight gain (defined as less than a 3% increase) 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 or without body weight measurement at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  7. Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG 26 Weeks After Randomisation

    Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  8. Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG Increment 26 Weeks After Randomisation

    Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The corresponding PPG increments were derived separately using each PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  9. Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile

    The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. The mean of the 7-9-7-point profile was defined as the area under the curve profile divided by the measurement time, and was calculated using the linear trapezoidal technique. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  10. Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG (Mean, Breakfast, Lunch, Main Evening Meal)

    The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Results were derived from the three profiles: post-breakfast, post-lunch, post-main evening meal. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  11. Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG Increment (Mean, Breakfast, Lunch, Main Evening Meal)

    The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. PPG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point and 9-point profile as the difference between PPG values and the PG value before the meal in each separate profile. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  12. Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile

    The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Fluctuation in SMPG profile was the average absolute difference from the mean of the SMPG profile. Change from baseline is represented as ratio to baseline value. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

    Time frame: Week 0, week 26

  13. Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Change in the Nocturnal Self-measured Plasma Glucose Measurements

    The subject was instructed to perform 7-9-7 SMPG point profile on 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast,60 minutes after the start of breakfast,before lunch,60 minutes after the start of lunch, before main evening meal,60 minutes after the start of main evening meal,and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on following day. Change from baseline in nocturnal PG values (nocturnal increments) was assessed by considering differences between PG values available at bedtime, at 4 a.m and the before breakfast value the following day: (04:00 PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 04:00 PG value). Results are based on the last in-trial value (the last available measurement in the in-trial period).

    Time frame: Week 0, week 26

  14. Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L

    Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  15. Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L Without Severe Hypoglycaemia

    Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation without severe hypoglycaemia. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  16. Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L and HbA1c <7.0% and Minimal Weight Gain (<3.0%) Without Severe Hypoglycaemia

    The percentage of subjects who achieved overall mean 1 hour PPG ≤7.8 mmol/L \[140 mg/dL\], had HbA1c \< 7.0% and had minimal weight gain (increase in body weight from baseline \<3.0%) 26 weeks after randomisation, and without severe hypoglycaemic episodes. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG or an HbA1c value or a body weight at week 26 were treated as non-responders.

    Time frame: 26 weeks after randomisation

  17. Change From Baseline in Lipids-lipoproteins Profile 26 Weeks After Randomisation (Total Cholesterol, High Density Lipoproteins [HDL] Cholesterol, Low Density Lipoproteins [LDL] Cholesterol)

    Change from baseline in HDL cholesterol, LDL cholesterol and total cholesterol 26 weeks after randomization are represented as ratio to baseline values. The results are based on the last in-trial value (the last available measurement in the in-trial period).

    Time frame: Week 0, week 26

  18. Insulin Dose (Basal Insulin Dose, Total and Individual Meal Insulin Dose)

    The insulin doses were summarised descriptively at week 0 and week 26 both by meal type and as total daily dose (total daily and separately for each mealtime dose). Week 26 results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  19. Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation

    A treatment emergent adverse event (TEAE) was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.

    Time frame: Week 0 to week 26 (+7 days)

  20. Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation

    A treatment emergent event was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.

    Time frame: Week 0 to week 26 (+7 days)

  21. Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall

    ADA classification includes following criteria: Severe,Documented symptomatic,Asymptomatic,Probable symptomatic,Pseudo-hypoglycaemia. NN Classification: * Severe:same as per ADA classification * Symptomatic blood glucose (BG) confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed:PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * BG confirmed:PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Treatment emergent episode: an event that has onset up to 1 day after last day of randomised treatment and excluding events occurring in run-in period.

    Time frame: Week 0 to week 26 (+1 day)

  22. Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: Daytime and Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)

    ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05:59 both inclusive.

    Time frame: Week 0 to week 26 (+1 day)

  23. Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: From Start of Meal Until 1,2, 4 Hours and From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal

    ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes related to meals.

    Time frame: Week 0 to week 26 (+1 day)

  24. Change From Baseline 26 Weeks After Randomisation in Clinical Evaluations (Physical Examination)

    The physical examination parameters included head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; and skin. The examinations were measured as 'normal', 'abnormal, not clinically significant' (Abn, NCS) or 'abnormal, clinically significant' (Abn, CS). Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 results are based on the last on-treatment value (last value), which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  25. Change From Baseline in Blood Pressure 26 Weeks After Randomisation

    Change from baseline in systolic blood pressure and diastolic blood pressure 26 weeks after randomisation. Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  26. Change From Baseline in Pulse 26 Weeks After Randomisation

    Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  27. Change From Baseline in Clinical Evaluation (Electrocardiogram) 26 Weeks After Randomisation

    The electrocardiogram was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  28. Change From Baseline in Clinical Evaluation (Fundoscopy/Fundus Photography) 26 Weeks After Randomisation

    The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  29. Change From Baseline in Erythrocytes 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  30. Change From Baseline in Haematocrit 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  31. Change From Baseline in Haemoglobin 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  32. Change From Baseline in Leukocytes 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  33. Change From Baseline in Thrombocytes 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  34. Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  35. Change From Baseline in Albumin 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  36. Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  37. Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  38. Change From Baseline in Total Bilirubin 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  39. Change From Baseline in Potassium 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  40. Change From Baseline in Creatinine 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  41. Change From Baseline in Total Protein 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  42. Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation

    Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  43. Change From Baseline in Urinalysis (Ketones) 26 Weeks After Randomisation

    Presence of ketone in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with ketone values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  44. Change From Baseline in Urinalysis (Protein) 26 Weeks After Randomisation

    Presence of protein in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with protein values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  45. Change From Baseline in Urinalysis (Erythrocytes) 26 Weeks After Randomisation

    Presence of erythrocytes in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with erythrocytes values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  46. Change From Baseline in Anti-insulin Aspart (Specific and Cross-reacting With Human Insulin) Antibody Development 26 Weeks After Randomisation

    Insulin aspart antibody titres (antibodies specific for insulin aspart and those cross-reacting with human insulin) measured at baseline and at 26 weeks. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period. Anti-insulin aspart antibody was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T).

    Time frame: Week 0, week 26

  47. Change From Baseline in Body Weight 26 Weeks After Randomisation

    The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

  48. Change From Baseline in Body Mass Index 26 Weeks After Randomisation

    The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

    Time frame: Week 0, week 26

08

Results

Posted Aug 10, 2018

Participant flow

The trial was conducted at 146 sites in 12 countries(number of sites indicates those that both screened and randomised subjects, unless otherwise noted)-Austria(4);Bulgaria(8); Canada(6); Germany(7); India(16); Israel(6); Italy(4); Japan(24); Russian Federation(10); Serbia(3); Taiwan(3); United States(55 sites screened/52 sites randomised subjects)

Participant flow — Overall Study
MilestoneFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Started342341342
Exposed342341342
Completed338334335
Not completed477
Withdrew: Adverse event001
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject464
Withdrew: Unclassified001

Outcome measures

PrimaryChange From Baseline in HbA1c 26 Weeks After Randomisation

Change from baseline (week 0) in HbA1c was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of HbA1c
Change From Baseline in HbA1c 26 Weeks After Randomisation
percentage of HbA1cFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in HbA1c 26 Weeks After Randomisation-0.12 ± 0.640.005 ± 0.64-0.09 ± 0.65
Statistical analysis
  • Faster Aspart (Meal) vs NovoRapid (Meal) · ANOVA model after multiple imputation · p = <0.001 (p-value from the 2-sided test for treatment difference evaluated at the 5% level) · Treatment difference: -0.02 · 95% CI -0.11 to 0.07
  • Faster Aspart (Post) vs NovoRapid (Meal) · ANOVA model after multiple imputation · p = <0.001 (p-value from the 2-sided test for treatment difference evaluated at the 5% level.) · Treatment difference: 0.10 · 95% CI 0.004 to 0.19
  • Faster Aspart (Meal) vs NovoRapid (Meal) · ANOVA model after multiple imputation · p = 0.633 (p-value from the 2-sided test for treatment difference evaluated at the 5% level) · Treatment difference: -0.02 · 95% CI -0.11 to 0.07
SecondaryChange From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)

The 1-hour PPG increment was analysed based on the laboratory-measured values in the meal test, and was derived using the 1-hour PPG measurement minus the pre-prandial plasma glucose (PG). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)-1.13 ± 4.041.04 ± 3.53-0.15 ± 3.78
Statistical analysis
  • Faster Aspart (Meal) vs NovoRapid (Meal) · ANOVA · p = <0.001 (p-value from the 2-sided test for treatment difference evaluated at the 5% level.) · Treatment difference: -0.90 · 95% CI -1.36 to -0.45
SecondaryChange From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation

The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · ug/mL
Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation
ug/mLFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation0.22 ± 2.23-0.15 ± 2.100.22 ± 2.25
Statistical analysis
  • Faster Aspart (Meal) vs NovoRapid (Meal) · ANOVA model after multiple imputation · p = 0.924 (p-values are from the 2-sided test for treatment difference evaluated at the 5% level.) · Treatment difference: 0.02 · 95% CI -0.31 to 0.34
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation

The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation0.17 ± 2.940.44 ± 3.290.64 ± 3.35
SecondaryPercentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0%) 26 Weeks After Randomisation

The percentage of subjects who achieved the HbA1c target of \<7.0% 26 weeks after randomisation. Subjects without an HbA1c measurement at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0%) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes28.728.232.7
No71.371.867.3
SecondaryPercentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia) 26 Weeks After Randomisation

The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes25.726.430.4
No74.373.669.6
SecondaryPercentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia and Minimal Weight Gain [<3.0%]) 26 Weeks After Randomisation

The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia and with minimal weight gain (defined as less than a 3% increase) 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 or without body weight measurement at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia and Minimal Weight Gain [<3.0%]) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes16.417.919.3
No83.682.180.7
SecondaryChange From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG 26 Weeks After Randomisation

Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG 26 Weeks After Randomisation
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in PPG at 30 min-0.47 ± 3.581.31 ± 3.520.21 ± 3.78
Change in PPG at 1 hour-1.05 ± 4.561.39 ± 4.440.20 ± 4.52
Change in PPG at 2 hours-0.41 ± 5.170.80 ± 5.380.33 ± 5.51
Change in PPG at 3 hours-0.12 ± 5.200.93 ± 5.060.51 ± 5.33
Change in PPG at 4 hours0.005 ± 4.640.83 ± 4.590.53 ± 4.60
SecondaryChange From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG Increment 26 Weeks After Randomisation

Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The corresponding PPG increments were derived separately using each PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG Increment 26 Weeks After Randomisation
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in PPG increment at 30 min-0.55 ± 2.550.94 ± 2.47-0.14 ± 2.63
Change in PPG increment at 1 hour-1.13 ± 4.041.04 ± 3.53-0.15 ± 3.78
Change in PPG increment at 2 hours-0.47 ± 4.740.42 ± 5.01-0.01 ± 5.15
Change in PPG increment at 3 hours-0.20 ± 4.890.55 ± 4.950.11 ± 5.32
Change in PPG increment at 4 hours-0.10 ± 4.470.45 ± 4.440.16 ± 4.63
SecondaryChange From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile

The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. The mean of the 7-9-7-point profile was defined as the area under the curve profile divided by the measurement time, and was calculated using the linear trapezoidal technique. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile-0.304 ± 1.928-0.231 ± 1.846-0.309 ± 2.060
SecondaryChange From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG (Mean, Breakfast, Lunch, Main Evening Meal)

The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Results were derived from the three profiles: post-breakfast, post-lunch, post-main evening meal. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG (Mean, Breakfast, Lunch, Main Evening Meal)
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in PPG breakfast-0.83 ± 3.34-0.03 ± 3.30-0.31 ± 3.18
Change in PPG lunch-0.59 ± 3.040.06 ± 2.98-0.33 ± 3.38
Change in PPG main evening meal-0.53 ± 3.55-0.01 ± 3.56-0.14 ± 3.22
Change in PPG all meals-0.65 ± 2.26-0.004 ± 2.19-0.25 ± 2.33
SecondaryChange From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG Increment (Mean, Breakfast, Lunch, Main Evening Meal)

The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. PPG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point and 9-point profile as the difference between PPG values and the PG value before the meal in each separate profile. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG Increment (Mean, Breakfast, Lunch, Main Evening Meal)
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in PPG increment breakfast-1.14 ± 3.640.06 ± 3.51-0.30 ± 3.16
Change in PPG increment lunch-0.67 ± 3.20-0.08 ± 3.10-0.004 ± 3.31
Change in PPG increment main evening meal-0.29 ± 3.700.34 ± 3.540.26 ± 3.49
Change in PPG increment all meals-0.72 ± 2.060.08 ± 1.98-0.02 ± 2.01
SecondaryChange From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile

The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Fluctuation in SMPG profile was the average absolute difference from the mean of the SMPG profile. Change from baseline is represented as ratio to baseline value. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile
ratioFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile0.876 ± 47.4900.875 ± 40.2930.890 ± 41.978
SecondaryChange From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Change in the Nocturnal Self-measured Plasma Glucose Measurements

The subject was instructed to perform 7-9-7 SMPG point profile on 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast,60 minutes after the start of breakfast,before lunch,60 minutes after the start of lunch, before main evening meal,60 minutes after the start of main evening meal,and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on following day. Change from baseline in nocturnal PG values (nocturnal increments) was assessed by considering differences between PG values available at bedtime, at 4 a.m and the before breakfast value the following day: (04:00 PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 04:00 PG value). Results are based on the last in-trial value (the last available measurement in the in-trial period).

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Change in the Nocturnal Self-measured Plasma Glucose Measurements
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in nocturnal increment-bedtime to 04:000.14 ± 5.660.19 ± 6.410.45 ± 5.55
Change in nocturnal increment-bedtime to breakfast0.86 ± 6.210.93 ± 6.240.33 ± 5.71
Change in nocturnal increment-04:00 to breakfast0.78 ± 4.951.01 ± 4.12-0.02 ± 4.17
SecondaryPercentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L

Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes27.819.921.6
No72.280.178.4
SecondaryPercentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L Without Severe Hypoglycaemia

Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation without severe hypoglycaemia. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L Without Severe Hypoglycaemia
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes24.618.820.5
No75.481.279.5
SecondaryPercentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L and HbA1c <7.0% and Minimal Weight Gain (<3.0%) Without Severe Hypoglycaemia

The percentage of subjects who achieved overall mean 1 hour PPG ≤7.8 mmol/L \[140 mg/dL\], had HbA1c \< 7.0% and had minimal weight gain (increase in body weight from baseline \<3.0%) 26 weeks after randomisation, and without severe hypoglycaemic episodes. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG or an HbA1c value or a body weight at week 26 were treated as non-responders.

Time frame:
26 weeks after randomisation
Reported as:
Number · percentage of subjects
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L and HbA1c <7.0% and Minimal Weight Gain (<3.0%) Without Severe Hypoglycaemia
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes7.64.78.2
No92.495.391.8
SecondaryChange From Baseline in Lipids-lipoproteins Profile 26 Weeks After Randomisation (Total Cholesterol, High Density Lipoproteins [HDL] Cholesterol, Low Density Lipoproteins [LDL] Cholesterol)

Change from baseline in HDL cholesterol, LDL cholesterol and total cholesterol 26 weeks after randomization are represented as ratio to baseline values. The results are based on the last in-trial value (the last available measurement in the in-trial period).

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Change From Baseline in Lipids-lipoproteins Profile 26 Weeks After Randomisation (Total Cholesterol, High Density Lipoproteins [HDL] Cholesterol, Low Density Lipoproteins [LDL] Cholesterol)
ratioFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
HDL cholesterol0.981 ± 16.2000.998 ± 17.2830.999 ± 33.056
LDL cholesterol1.025 ± 20.0671.053 ± 22.4651.062 ± 215.570
Total cholesterol1.002 ± 14.5611.030 ± 15.7891.020 ± 15.891
SecondaryInsulin Dose (Basal Insulin Dose, Total and Individual Meal Insulin Dose)

The insulin doses were summarised descriptively at week 0 and week 26 both by meal type and as total daily dose (total daily and separately for each mealtime dose). Week 26 results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · Units
Insulin Dose (Basal Insulin Dose, Total and Individual Meal Insulin Dose)
UnitsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Daily bolus insulin dose: week 025.5 ± 15.425.4 ± 14.326.6 ± 14.8
Daily bolus insulin dose: Last on-treatment value31.1 ± 19.430.5 ± 18.933.5 ± 22.5
Daily basal insulin dose: week 025.3 ± 14.526.7 ± 15.626.2 ± 15.0
Daily basal insulin dose: Last on-treatment value26.7 ± 16.627.3 ± 16.827.2 ± 17.3
Total daily insulin dose: week 050.8 ± 26.152.2 ± 25.253.1 ± 25.9
Total daily insulin dose: Last on-treatment value57.7 ± 31.457.8 ± 30.260.4 ± 34.0
Daily breakfast bolus insulin dose: Last value8.8 ± 6.28.6 ± 6.09.5 ± 7.7
Daily lunch bolus insulin dose: Last value10.5 ± 7.010.3 ± 6.911.2 ± 7.6
Daily main evening meal bolus insulin: Last value11.9 ± 7.711.6 ± 7.412.7 ± 9.1
Daily other bolus insulin dose: Last value4.7 ± 5.14.3 ± 3.54.2 ± 3.3
SecondaryNumber of Treatment Emergent Adverse Events During 26 Weeks After Randomisation

A treatment emergent adverse event (TEAE) was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.

Time frame:
Week 0 to week 26 (+7 days)
Reported as:
Number · events
Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation
eventsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation649656627
SecondaryNumber of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation

A treatment emergent event was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.

Time frame:
Week 0 to week 26 (+7 days)
Reported as:
Number · Injection site reactions
Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation
Injection site reactionsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation91210
SecondaryNumber of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall

ADA classification includes following criteria: Severe,Documented symptomatic,Asymptomatic,Probable symptomatic,Pseudo-hypoglycaemia. NN Classification: * Severe:same as per ADA classification * Symptomatic blood glucose (BG) confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed:PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * BG confirmed:PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Treatment emergent episode: an event that has onset up to 1 day after last day of randomised treatment and excluding events occurring in run-in period.

Time frame:
Week 0 to week 26 (+1 day)
Reported as:
Number · hypoglycaemic episodes
Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall
hypoglycaemic episodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall157601657916520
SecondaryNumber of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: Daytime and Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)

ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05:59 both inclusive.

Time frame:
Week 0 to week 26 (+1 day)
Reported as:
Number · hypoglycaemic episodes
Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: Daytime and Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
hypoglycaemic episodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Daytime hypoglycaemic episodes145701537915257
Nocturnal hypoglycaemic episodes119012001263
SecondaryNumber of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: From Start of Meal Until 1,2, 4 Hours and From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal

ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes related to meals.

Time frame:
Week 0 to week 26 (+1 day)
Reported as:
Number · hypoglycaemic episodes
Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: From Start of Meal Until 1,2, 4 Hours and From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal
hypoglycaemic episodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Within 1 hour after meal624614459
Within 2 hours after meal131414701224
Within 4 hours after meal392047944129
Between 1 (exclusive) to 2 hours (inclusive)690856765
Between 2 (exclusive) to 3 hours (inclusive)123616341302
Between 2 (exclusive) to 4 hours (inclusive)260633242905
Between 3 (exclusive) to 4 hours (inclusive) hours137016901603
SecondaryChange From Baseline 26 Weeks After Randomisation in Clinical Evaluations (Physical Examination)

The physical examination parameters included head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; and skin. The examinations were measured as 'normal', 'abnormal, not clinically significant' (Abn, NCS) or 'abnormal, clinically significant' (Abn, CS). Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 results are based on the last on-treatment value (last value), which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline 26 Weeks After Randomisation in Clinical Evaluations (Physical Examination)
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Cardiovascular system - Week 0: Normal97.498.897.7
Cardiovascular system - Week 0: Abn, NCS2.60.92.0
Cardiovascular system - Week 0: Abn, CS0.00.30.3
Cardiovascular system - Last value: Normal97.498.897.9
Cardiovascular system - Last value: Abn, NCS2.60.91.8
Cardiovascular system - Last value: Abn, CS0.00.30.3
Nervous system - Week 0: Normal83.986.886.3
Nervous system - Week 0: Abn, NCS15.512.913.2
Nervous system - Week 0: Abn, CS0.60.30.6
Nervous system - Last value: Normal83.887.186.8
Nervous system - Last value: Abn, NCS15.612.912.4
Nervous system - Last value: Abn, CS0.60.00.9
Gastrointestinal system-week 0: Normal99.798.898.2
Gastrointestinal system-week 0: Abn, NCS0.30.90.9
Gastrointestinal system-week 0: Abn, CS0.00.30.9
Gastrointestinal system-Last value: Normal99.197.998.5
Gastrointestinal system-Last value: Abn, NCS0.91.20.6
Gastrointestinal system-Last value: Abn, CS0.00.90.9
Head,ears,eyes,nose,throat,neck:week 0-Normal95.095.693.3
Head,ear,eye,nose,throat,neck-week 0:Abn,NCS4.13.85.8
Head,ears,eyes,nose,throat,neck-week 0:Abn,CS0.90.60.9
Head,ears,eyes,nose,throat,neck-Last value:Normal95.392.994.1
Head,ear,eye,nose,throat,neck-Last value:Abn,NCS3.86.24.4
Head,ear,eye,nose,throat,neck-Last value:Abn,CS0.90.91.5
Musculoskeletal system-week 0: Normal95.997.196.2
Musculoskeletal system-week 0: Abn, NCS4.12.93.5
Musculoskeletal system-week 0: Abn, CS0.00.00.3
Musculoskeletal system-Last value: Normal96.897.495.3
Musculoskeletal system-Last value: Abn, NCS3.22.63.8
Musculoskeletal system-Last value: Abn, CS0.00.00.9
Respiratory system-week 0: Normal99.499.499.1
Respiratory system-week 0: Abn, NCS0.60.30.6
Respiratory system-week 0: Abn, CS0.00.30.3
Respiratory system-Last value: Normal99.799.499.4
Respiratory system-Last value: Abn, NCS0.30.30.3
Respiratory system-Last value: Abn, CS0.00.30.3
Skin-week 0: Normal91.589.791.5
Skin-week 0: Abn, NCS7.38.87.9
Skin-week 0: Abn, CS1.21.50.6
Skin-Last value: Normal91.591.592.4
Skin-Last value: Abn, NCS7.66.26.5
Skin-Last value: Abn, CS0.92.41.2
SecondaryChange From Baseline in Blood Pressure 26 Weeks After Randomisation

Change from baseline in systolic blood pressure and diastolic blood pressure 26 weeks after randomisation. Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmHg
Change From Baseline in Blood Pressure 26 Weeks After Randomisation
mmHgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Diastolic blood pressure0.5 ± 8.30.2 ± 7.80.8 ± 7.9
Systolic blood pressure0.6 ± 12.51.4 ± 10.80.8 ± 12.9
SecondaryChange From Baseline in Pulse 26 Weeks After Randomisation

Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · beats/minute
Change From Baseline in Pulse 26 Weeks After Randomisation
beats/minuteFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Pulse 26 Weeks After Randomisation0.0 ± 8.8-0.7 ± 9.30.7 ± 8.3
SecondaryChange From Baseline in Clinical Evaluation (Electrocardiogram) 26 Weeks After Randomisation

The electrocardiogram was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline in Clinical Evaluation (Electrocardiogram) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Week 0: Normal80.781.884.2
Week 0: Abn, NCS19.317.615.8
Week 0: Abn, CS0.00.60.0
Last on-treatment value: Normal80.884.082.3
Last on-treatment value: Abn, NCS19.215.117.1
Last on-treatment value: Abn, CS0.00.90.6
SecondaryChange From Baseline in Clinical Evaluation (Fundoscopy/Fundus Photography) 26 Weeks After Randomisation

The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline in Clinical Evaluation (Fundoscopy/Fundus Photography) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Left eye-Week 0: Normal65.868.069.3
Left eye-Week 0: Abn, NCS26.923.523.4
Left eye-Week 0: Abn, CS7.38.57.3
Left eye-Last on-treatment value: Normal62.569.469.3
Left eye-Last on-treatment value: Abn, NCS29.721.021.1
Left eye-Last on-treatment value: Abn, CS7.89.69.6
Right eye-Week 0: Normal65.268.967.0
Right eye-Week 0: Abn, NCS27.822.325.4
Right eye-Week 0: Abn, CS7.08.87.6
Right eye-Last on-treatment value: Normal64.067.968.7
Right eye-Last on-treatment value: Abn, NCS29.122.522.6
Right eye-Last on-treatment value: Abn, CS6.99.68.7
SecondaryChange From Baseline in Erythrocytes 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · number of erythrocytes 10^12/L
Change From Baseline in Erythrocytes 26 Weeks After Randomisation
number of erythrocytes 10^12/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Erythrocytes 26 Weeks After Randomisation-0.01 ± 0.24-0.03 ± 0.26-0.02 ± 0.26
SecondaryChange From Baseline in Haematocrit 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of red blood cells in blood
Change From Baseline in Haematocrit 26 Weeks After Randomisation
percentage of red blood cells in bloodFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Haematocrit 26 Weeks After Randomisation-0.48 ± 2.58-0.52 ± 2.41-0.57 ± 2.45
SecondaryChange From Baseline in Haemoglobin 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Haemoglobin 26 Weeks After Randomisation
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Haemoglobin 26 Weeks After Randomisation-0.04 ± 0.51-0.04 ± 0.46-0.05 ± 0.50
SecondaryChange From Baseline in Leukocytes 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · Number of leukocytes 10^9/L
Change From Baseline in Leukocytes 26 Weeks After Randomisation
Number of leukocytes 10^9/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Leukocytes 26 Weeks After Randomisation-0.17 ± 1.63-0.03 ± 1.52-0.01 ± 1.46
SecondaryChange From Baseline in Thrombocytes 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · Number of thrombocytes 10^9/L
Change From Baseline in Thrombocytes 26 Weeks After Randomisation
Number of thrombocytes 10^9/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Thrombocytes 26 Weeks After Randomisation-0.7 ± 40.0-2.0 ± 36.3-1.8 ± 33.7
SecondaryChange From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation1.3 ± 10.10.9 ± 9.00.6 ± 11.6
SecondaryChange From Baseline in Albumin 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · g/dL
Change From Baseline in Albumin 26 Weeks After Randomisation
g/dLFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Albumin 26 Weeks After Randomisation-0.02 ± 0.25-0.05 ± 0.25-0.03 ± 0.25
SecondaryChange From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation2.1 ± 18.91.4 ± 12.3-0.2 ± 14.4
SecondaryChange From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation-0.0 ± 9.5-0.1 ± 9.4-0.3 ± 13.3
SecondaryChange From Baseline in Total Bilirubin 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin 26 Weeks After Randomisation
umol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Total Bilirubin 26 Weeks After Randomisation-0.1 ± 3.3-0.2 ± 3.9-0.2 ± 3.3
SecondaryChange From Baseline in Potassium 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Potassium 26 Weeks After Randomisation
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Potassium 26 Weeks After Randomisation0.01 ± 0.430.04 ± 0.420.04 ± 0.43
SecondaryChange From Baseline in Creatinine 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · umol/L
Change From Baseline in Creatinine 26 Weeks After Randomisation
umol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Creatinine 26 Weeks After Randomisation2.0 ± 8.81.8 ± 7.51.8 ± 15.6
SecondaryChange From Baseline in Total Protein 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · g/dL
Change From Baseline in Total Protein 26 Weeks After Randomisation
g/dLFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Total Protein 26 Weeks After Randomisation0.03 ± 0.400.02 ± 0.37-0.02 ± 0.36
SecondaryChange From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation

Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · mg/mmol
Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation
mg/mmolFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation0.636 ± 7.361-0.379 ± 11.0950.656 ± 12.739
SecondaryChange From Baseline in Urinalysis (Ketones) 26 Weeks After Randomisation

Presence of ketone in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with ketone values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline in Urinalysis (Ketones) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Week 0: Negative96.297.192.7
Week 0: Positive0.00.00.0
Week 0: Trace2.01.85.3
Week 0: 1+1.81.21.8
Week 0: 2+0.00.00.3
Week 0: 3+0.00.00.0
Last on-treatment value: Negative92.389.790.0
Last on-treatment value:Positive0.00.00.0
Last on-treatment value: Trace5.06.56.5
Last on-treatment value:1+2.13.22.9
Last on-treatment value: 2+0.60.60.6
Last on-treatment value: 3+0.00.00.0
SecondaryChange From Baseline in Urinalysis (Protein) 26 Weeks After Randomisation

Presence of protein in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with protein values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline in Urinalysis (Protein) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Week 0: Negative82.279.580.4
Week 0: Positive0.00.00.0
Week 0: Trace12.014.413.5
Week 0: 1+4.44.13.5
Week 0: 2+1.21.22.0
Week 0: 3+0.30.90.6
Last on-treatment value: Negative83.582.678.8
Last on-treatment value:Positive0.00.00.0
Last on-treatment value: Trace8.610.912.4
Last on-treatment value:1+5.94.76.5
Last on-treatment value: 2+1.51.22.1
Last on-treatment value: 3+0.60.60.3
SecondaryChange From Baseline in Urinalysis (Erythrocytes) 26 Weeks After Randomisation

Presence of erythrocytes in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with erythrocytes values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Number · percentage of subjects
Change From Baseline in Urinalysis (Erythrocytes) 26 Weeks After Randomisation
percentage of subjectsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Week 0: Negative95.393.393.3
Week 0: Positive0.00.00.0
Week 0: Trace1.82.33.2
Week 0: 1+0.91.52.0
Week 0: 2+1.20.90.6
Week 0: 3+0.92.10.9
Last on-treatment value: Negative93.591.791.8
Last on-treatment value:Positive0.00.00.0
Last on-treatment value: Trace2.73.82.6
Last on-treatment value:1+1.50.92.1
Last on-treatment value: 2+0.62.11.8
Last on-treatment value: 3+1.81.51.8
SecondaryChange From Baseline in Anti-insulin Aspart (Specific and Cross-reacting With Human Insulin) Antibody Development 26 Weeks After Randomisation

Insulin aspart antibody titres (antibodies specific for insulin aspart and those cross-reacting with human insulin) measured at baseline and at 26 weeks. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period. Anti-insulin aspart antibody was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T).

Time frame:
Week 0, week 26
Reported as:
Mean · % B/T
Change From Baseline in Anti-insulin Aspart (Specific and Cross-reacting With Human Insulin) Antibody Development 26 Weeks After Randomisation
% B/TFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Anti-insulin aspart specific antibodies0.033 ± 0.777-0.027 ± 1.077-0.013 ± 1.568
Cross-reacting to human insulin-0.972 ± 6.028-1.799 ± 6.812-1.427 ± 5.527
SecondaryChange From Baseline in Body Weight 26 Weeks After Randomisation

The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight 26 Weeks After Randomisation
kgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Body Weight 26 Weeks After Randomisation1.43 ± 2.661.14 ± 2.951.24 ± 2.60
SecondaryChange From Baseline in Body Mass Index 26 Weeks After Randomisation

The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.

Time frame:
Week 0, week 26
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index 26 Weeks After Randomisation
kg/m^2Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change From Baseline in Body Mass Index 26 Weeks After Randomisation0.49 ± 0.910.39 ± 1.020.43 ± 0.89

Adverse events

Collected over Week 0 to week 26 (+7 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Faster Aspart (Meal)0/342 (0%)20/342 (5.8%)154/342 (45%)
Faster Aspart (Post)0/341 (0%)17/341 (5%)152/341 (44.6%)
NovoRapid (Meal)0/342 (0%)17/342 (5%)161/342 (47.1%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
HypoglycaemiaMetabolism and nutrition disorders8/3423/3416/342
Hypoglycaemic unconsciousnessNervous system disorders2/3423/3412/342
PolyneuropathyNervous system disorders0/3422/3410/342
Hypoglycaemic seizureNervous system disorders2/3421/3410/342
Wrong drug administeredInjury, poisoning and procedural complications0/3420/3412/342
BursitisMusculoskeletal and connective tissue disorders0/3421/3410/342
CellulitisInfections and infestations0/3421/3410/342
Cerebrovascular accidentNervous system disorders0/3421/3410/342
Chest painGeneral disorders0/3421/3410/342
Diabetic metabolic decompensationMetabolism and nutrition disorders1/3421/3411/342
Most frequent other events
Most frequent other events
EventFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Viral upper respiratory tract infectionInfections and infestations73/34270/34180/342
Blood glucose decreasedInvestigations58/34267/34168/342
Upper respiratory tract infectionInfections and infestations30/34226/34127/342
InfluenzaInfections and infestations21/34214/34110/342

Baseline characteristics

Full analysis set (FAS) included all randomised subjects.

Age, Continuous
Age, Continuous(years)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Mean41.48 ± 14.4241.02 ± 14.5940.77 ± 14.2241.09 ± 14.40
Sex: Female, Male
Sex: Female, Male(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Female158155163476
Male184186179549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Hispanic or Latino1381233
Not Hispanic or Latino329333330992
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
American Indian or Alaska Native1012
Asian116131137384
Native Hawaiian or Other Pacific Islander0000
Black or African American64616
White219206198623
More than one race0000
Unknown or Not Reported0000
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percentage of HbA1c)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Mean7.46 ± 0.687.40 ± 0.607.41 ± 0.797.42 ± 0.70
09

Study locations

152 sites
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85714, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Fullerton, California 92835, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92648, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    Newport Beach, California 92663, United States
  • Novo Nordisk Investigational Site
    Santa Barbara, California 93105, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80209, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33607, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21204, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Flint, Michigan 48503-5904, United States
  • Novo Nordisk Investigational Site
    Kalamazoo, Michigan 49048, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Jefferson City, Missouri 65109, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Hamilton, New Jersey 08690, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87109-2134, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Rochester, New York 14607, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Bend, Oregon 97702, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78749, United States
  • Novo Nordisk Investigational Site
    Beaumont, Texas 77701, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75218, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Mesquite, Texas 75149, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    Murray, Utah 84123, United States
  • Novo Nordisk Investigational Site
    Ogden, Utah 84405, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84102, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Federal Way, Washington 98003, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99201, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5020, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Dimitrovgrad, 6400, Bulgaria
  • Novo Nordisk Investigational Site
    Pleven, 5800, Bulgaria
  • Novo Nordisk Investigational Site
    Plovdiv, 4002, Bulgaria
  • Novo Nordisk Investigational Site
    Ruse, 7000, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1431, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1606, Bulgaria
  • Novo Nordisk Investigational Site
    Varna, 9010, Bulgaria
  • Novo Nordisk Investigational Site
    Calgary, Alberta T2H 2G4, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H2W 1R7, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G2, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G5, Canada
  • Novo Nordisk Investigational Site
    Berlin, 12163, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13597, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01219, Germany
  • Novo Nordisk Investigational Site
    Falkensee, 14612, Germany
  • Novo Nordisk Investigational Site
    Lingen, 49808, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Schweinfurt, 97421, Germany
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500072, India
  • Novo Nordisk Investigational Site
    Visakhapatnam, Andhra Pradesh 530002, India
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380006, India
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380052, India
  • Novo Nordisk Investigational Site
    Rohtak, Haryana 124001, India
  • Novo Nordisk Investigational Site
    Kozhikode, Kerala 673017, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452008, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452010, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411001, India
  • Novo Nordisk Investigational Site
    Bhubaneswar, Orissa 751019, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600 013, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600086, India
  • Novo Nordisk Investigational Site
    Vellore, Tamil Nadu 632004, India
  • Novo Nordisk Investigational Site
    Chandigarh, 160012, India
  • Novo Nordisk Investigational Site
    New Dehli, 110029, India
  • Novo Nordisk Investigational Site
    New Delhi, 110001, India
  • Novo Nordisk Investigational Site
    Pune, 411011, India
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel

Showing the first 100 of 152 sites across 13 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Rose L, Kadowaki T, Pieber TR, Buchholtz K, Ekelund M, Gorst-Rasmussen A, Philis-Tsimikas A. Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. Diabetes Ther. 2019 Jun;10(3):1029-1041. doi: 10.1007/s13300-019-0608-4. Epub 2019 Apr 4. PubMed 30949906 ↗
  • Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B, Buchholtz K, Horio H, Kadowaki T. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab. 2018 Dec;20(12):2885-2893. doi: 10.1111/dom.13545. Epub 2018 Oct 10. PubMed 30259644 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jul 2017, 14 months.

Results were first posted in Aug 2018, 1 year after primary completion.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 14 months is below that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2015
First posted
Jul 16, 2015
StartActual
May 4, 2016
Primary completionActual
Jul 17, 2017
CompletionActual
Aug 16, 2017
Results first posted
Aug 10, 2018
Last update
Jun 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02500706
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
May 4, 2016
Primary completion
Jul 17, 2017
Completion
Aug 16, 2017
Results posted
Aug 10, 2018
Last update
Jun 12, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion